Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
spacer
Blue curve MMWR spacer
spacer
spacer

The content on this page is being archived for historic and reference purposes only. The content, links, and pdfs are no longer maintained and might be outdated.

Summary Table. Rotavirus Vaccine for the Prevention of Rotavirus Gas Among Children Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Summary Table. Recommendations and Quality of Evidence

Rotavirus Vaccine Recommendations Advisory Committee on Immunization Practices, 1999 (Table_1)
Table_1
Note: To print large tables and graphs users may have to change their printer settings to landscape and use a small font size.


Summary Table. Recommendations and Quality of Evidence
Rotavirus Vaccine Recommendations Advisory Committee on Immunization Practices, 1999
=====================================================================================================================================
                                                                                                       Level of         Strength of
Recommendations                                                                                       Evidence*          Evidence+
-------------------------------------------------------------------------------------------------------------------------------------
Provide routine vaccination at 2,4,and 6 months of age.                                                   I                  A
Administer to breastfed infants.                                                                          I                  A
Administer with DTP (or DTaP),Hib vaccine,OPV,IPV,and hepatitis B vaccine.                                I                  A
Administer to infants with mild illnesses.                                                                I                  B
Not recommended for
Infants with known or suspected immunodeficiency                                                         III                 C
Infants with hypersensitivity to vaccine components                                                      III                 B
Infants with acute gastrointestinal disease                                                              III                 C
Infants with moderate to severe febrile illness                                                          III                 C
Precautions and special situations
Premature infants (<37 weeks gestational age)                                                            III                 C
Infants living in households with immunocompromised persons                                              III                 C
Timing of administration of antibody-containing blood products and rotavirus vaccination                 III                 C
Infants with preexisting chronic gastrointestinal illnesses                                              III                 C
Vaccine that is regurgitated                                                                             III                 C
Late or incomplete immunization                                                                          III                 C
Children hospitalized after vaccination                                                                  III                 C
-------------------------------------------------------------------------------------------------------------------------------------
* Level of Evidence
I Evidence from randomized, controlled trials
II Evidence from other epidemiologic studies
III Opinions of authorities

+ Strength of Evidence
A Good evidence to support recommendation
B Fair evidence to support recommendation
C Insufficient evidence
=====================================================================================================================================

Return to top.

Disclaimer   All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Page converted: 03/18/99

HOME  |  ABOUT MMWR  |  MMWR SEARCH  |  DOWNLOADS  |  RSSCONTACT
POLICY  |  DISCLAIMER  |  ACCESSIBILITY

Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A

USA.GovDHHS

Department of Health
and Human Services

This page last reviewed 5/2/01